For anyone who is interested I have received this email from the pharmaceutical company who make Ozempic, NovoNordisk in response to a query regarding splitting the dose and extra doses in the pen:
Ozempic®‚(semaglutide) – Licensed indication
Ozempic is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in addition to other medicinal products for the treatment of diabetes.
*
Splitting the doses:
Semaglutide should be administered once weekly, on the same day each week, at any time of the day, with or without meals. Semaglutide should be administered subcutaneously in the abdomen, thigh, or upper arm.
Novo Nordisk has not studied alternative dosing regimens, including splitting the dose. Novo Nordisk has only evaluated semaglutide in clinical studies as a once-weekly subcutaneous injection. *
*
Extra doses in the pen:
Extra doses are provided to prime the pen. If a patient needs to prime more than once, extra doses are available in the pen to allow them to do so as advised in the patient information leaflet.(1)*
I hope this information is of assistance, but if we can be of any further help, please do not hesitate to contact us again.
Yours sincerely,
Sai Priyanka Vungarala*
On behalf of the Medical Information Team
Novo Nordisk Ltd, 1st Floor, 3 City Place, Beehive Ring Road, Gatwick, West Sussex,RH6 0PA, England Tel: +44 (0) 1293 613 555 Fax: +44 (0) 1293 613 535 Web: www.novonordisk.co.ukukk* Registered Office: As above Reg. No: 1118740_ The United Kingdom
As you can see, the extra doses are to prime the pen and there is no clinical data for splitting doses.